Partial nephrectomy for T2 renal masses: contemporary trends and oncologic efficacy
- PMID: 25864101
- DOI: 10.1007/s11255-015-0975-3
Partial nephrectomy for T2 renal masses: contemporary trends and oncologic efficacy
Abstract
Purpose: Increasing popularity and improved technical feasibility of partial nephrectomy (PN) has encouraged urologists to treat larger renal masses with nephron-sparing surgery. We used a national database to characterize practice patterns for the surgical management of patients with T2 renal tumors and examined the effect of PN on cancer-specific survival in such patients.
Methods: Between 2001 and 2011, 10,259 patients with primary tumor size >7 cm confined to the kidney (T2) were treated surgically for kidney cancer. PN trends were examined using annual percentage change (APC). Multivariate survival models were developed to identify independent determinants of PN use and cancer-specific survival (CSS) following surgical treatment of kidney cancer.
Results: Overall, 543 patients (5.29 %) were treated with PN versus 9716 (94.71 %) who underwent radical nephrectomy (RN). The use of PN increased progressively between 2001 and 2011 (APC +11.1 %, p < 0.05). Male gender, geographic location, year of diagnosis, and disease stage were independent determinants of increased PN use (all p values <0.05). Cancer-specific mortality was not inferior for patients treated with PN versus RN (HR 0.68, 95 % CI 0.50-0.94). Male gender, younger age, white race, tumor size >10 cm, localized disease, and papillary histology were all associated with improved CSS with PN (all p values <0.05).
Conclusions: PN is increasingly utilized to treat T2 renal masses. Our analysis demonstrates that PN for T2 renal masses has no contraindicated effect on CSS.
Similar articles
-
Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib-II renal masses: An analysis of the national cancer data base.Cancer. 2018 Oct 1;124(19):3839-3848. doi: 10.1002/cncr.31582. Epub 2018 Sep 12. Cancer. 2018. PMID: 30207380
-
Partial nephrectomy for small renal masses: an emerging quality of care concern?J Urol. 2006 Mar;175(3 Pt 1):853-7; discussion 858. doi: 10.1016/S0022-5347(05)00422-2. J Urol. 2006. PMID: 16469564
-
Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach.BJU Int. 2012 May;109(10):1457-62. doi: 10.1111/j.1464-410X.2011.10597.x. Epub 2011 Sep 20. BJU Int. 2012. PMID: 21933334
-
The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications.Eur Urol. 2010 Feb;57(2):214-22. doi: 10.1016/j.eururo.2009.10.019. Epub 2009 Oct 20. Eur Urol. 2010. PMID: 19853988 Review.
-
Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses.Eur Urol. 2017 Jul;72(1):64-75. doi: 10.1016/j.eururo.2016.11.038. Epub 2016 Dec 14. Eur Urol. 2017. PMID: 27988238 Review.
Cited by
-
Surgical Strategies in Renal Cancer: A Meta-analysis of Partial vs. Radical Nephrectomy Outcomes Across Tumor Stages.Qatar Med J. 2025 Jun 9;2025(2):54. doi: 10.5339/qmj.2025.54. eCollection 2025. Qatar Med J. 2025. PMID: 40556844 Free PMC article. Review.
-
Outlining the limits of partial nephrectomy.Transl Androl Urol. 2015 Jun;4(3):294-300. doi: 10.3978/j.issn.2223-4683.2015.06.04. Transl Androl Urol. 2015. PMID: 26236649 Free PMC article.
-
Histopathological validation of safe margin for nephron-sparing surgery based on individual tumor growth pattern.World J Surg Oncol. 2021 Aug 28;19(1):255. doi: 10.1186/s12957-021-02375-3. World J Surg Oncol. 2021. PMID: 34454535 Free PMC article.
-
Patient Factors Impacting Perioperative Outcomes for T1b-T2 Localized Renal Cell Carcinoma May Guide Decision for Partial versus Radical Nephrectomy.J Clin Med. 2022 Dec 26;12(1):175. doi: 10.3390/jcm12010175. J Clin Med. 2022. PMID: 36614976 Free PMC article.
-
Time trends in surgical provision and cancer-specific outcomes in patients with stage T2-3 kidney cancer: a SEER-based study.Front Surg. 2024 Apr 29;11:1370702. doi: 10.3389/fsurg.2024.1370702. eCollection 2024. Front Surg. 2024. PMID: 38742149 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical